New immunotherapy combo tackles Hard-to-Treat cancers

NCT ID NCT04423029

Completed Disease control Sponsor: Dragonfly Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and get an early look at whether the drugs shrink tumors. Because it is a Phase 1 study, the focus is on safety and dosing, not on proving the treatment works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DF6002 (an experimental immunotherapy) and nivolumab (Opdivo, an approved immunotherapy)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early (Phase 1) trial with only 170 participants, so the main goals are safety and dosing—not proof of effectiveness. Many early-stage cancer drugs fail to show benefit in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS

Contacts and locations

Locations

Atlantic Health System

Morristown, New Jersey, 07960, United States
Augusta University Georgia Cancer Center

Augusta, Georgia, 30912-0003, United States
Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Centre Hospitalier Lyon-Sud

Pierre-Bénite, 69495, France
Clinica Universidad de Navarra - Madrid

Madrid, 28027, Spain
Clinica Universidad de Navarra - Pamplona

Pamplona, 31008, Spain
Froedtert Hospital

Milwaukee, Wisconsin, 53226, United States
Gustave Roussy

Villejuif, 94805, France
HealthPartners Cancer Center at Regions Hospital

Saint Paul, Minnesota, 55101, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
Hospital Universitari Vall d'Hebrón

Barcelona, 08035, Spain
Hospital Universitario Ramón y Cajal

Madrid, 28034, Spain
Huntsman Cancer Institute and Hospital

Salt Lake City, Utah, 84112, United States
Hôpital Saint-Louis

Paris, 75010, France
Institut Bergonié

Bordeaux, 33000, France
Local Institution

Boston, Massachusetts, 02215, United States
Local Institution - 0022

Heidelberg, 3084, Australia
Local Institution - 0023

Box Hill, 3128, Australia
Montefiore Medical Center

The Bronx, New York, 10467, United States
Rhode Island Hospital

Providence, Rhode Island, 02903, United States
Roswell Park Comprehensive Cancer Center

Buffalo, New York, 14263, United States
SCRI - HealthOne Denver

Denver, Colorado, 80218, United States
SCRI - Tennessee Oncology - Saint Thomas West Clinic

Nashville, Tennessee, 37205, United States
START Madrid - Hospital Universitario Fundación Jiménez Díaz

Madrid, 28040, Spain
Stephenson Cancer Center

Oklahoma City, Oklahoma, 73104, United States
USOR - Virginia Cancer Specialists - Fairfax Office

Fairfax, Virginia, 22031, United States
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of California Irvine

Orange, California, 92868, United States
University of Iowa Hospitals and Clinics

Iowa City, Iowa, 52242, United States
University of Miami

Miami, Florida, 33136, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Yale School of Medicine

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.